导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.88% | 1520/4773 |
| 近一周 | -1.26% | 1909/5465 |
| 近一月 | -8.06% | 4757/5421 |
| 近一季 | -17.96% | 4660/5231 |
| 近半年 | -0.57% | 1514/4920 |
| 近一年 | 7.61% | 1451/4394 |
| 近两年 | 108.57% | 562/2954 |
| 近三年 | 64.13% | 422/2253 |
| 成立以来 | 182.17% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.57% 1851/4961 |
34.31% 957/5312 |
- - |
- - |
| 2025 | 47.75% 552/4813 |
-1.59% 2700/3635 |
3.14% 1141/4076 |
46.98% 496/4524 |
-0.97% 2748/4813 |
| 2024 | 12.72% 1216/3463 |
-3.72% 1551/2808 |
-6.12% 1856/3014 |
27.39% 227/3129 |
-2.10% 1954/3463 |
| 2023 | -17.85% 1764/2656 |
1.99% 1468/2280 |
-6.77% 1703/2385 |
-8.91% 1747/2515 |
-5.16% 1277/2655 |
| 2022 | -26.95% 1445/2207 |
-18.54% 1351/1919 |
5.84% 816/2016 |
-17.24% 1567/2113 |
2.37% 958/2208 |
| 2021 | 13.24% 360/1822 |
-6.09% 975/1255 |
25.05% 99/1330 |
-5.96% 882/1466 |
2.54% 566/1822 |
| 2020 | 63.26% 107/1250 |
4.12% 86/1028 |
28.63% 97/1067 |
6.43% 839/1164 |
14.54% 266/1184 |
| 2019 | 39.82% 269/1092 |
32.12% 181/754 |
-9.65% 676/804 |
7.10% 101/850 |
9.37% 230/918 |
| 2018 | -29.30% 449/834 |
- - |
- - |
- - |
-12.70% 475/691 |
| 2017 | 25.75% 111/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.87% 230/605 |
- - |
- - |
- - |
- - |
| 2015 | 25.74% 89/575 |
- - |
- - |
- - |
- - |
| 2014 | 46.48% 101/237 |
- - |
- - |
- - |
- - |
| 2013 | -3.61% 78/186 |
- - |
- - |
- - |
- - |
| 2012 | 0.66% 113/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 博时创业板ETF联接A VS. 长安沪深300非周期A(740101) |